SOUTH
SAN FRANCISCO, Calif., Nov. 12,
2024 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(NASDAQ: IDYA), a precision medicine oncology company committed to
the discovery and development of targeted therapeutics, announced
its participation in the Jefferies London Healthcare Conference and
its plans to host an Investor R&D Day in December 2024.
Jefferies London Healthcare Conference
Tuesday, November 19th,
2024 at 10:00 AM GMT | 5:00 AM ET
- Fireside chat with Yujiro S.
Hata, Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst,
Biotechnology
IDEAYA Biosciences Investor R&D Day
Monday, December 16th,
2024 at 8:00 AM ET
- The IDEAYA Investor R&D Day will highlight IDEAYA's
potential first-in-class preclinical and clinical pipeline with
management, leading Key Opinion Leader(s) (KOLs), and Pharma
partner(s)
- Pre-registration will be available through IDEAYA's investor
relations events page at https://ir.ideayabio.com/events, or
https://lifescievents.com/event/ideaya-4/
A live audio webcast of the conference event, as permitted by
the conference host, will be available at the "Investors/Events"
section of the IDEAYA website at https://ir.ideayabio.com/events
and/or through the conference host. A replay of the webcast will be
accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's
approach integrates capabilities in identifying and validating
translational biomarkers with drug discovery to select patient
populations most likely to benefit from its targeted
therapies. IDEAYA is applying its early research and drug
discovery capabilities to synthetic lethality – which represents an
emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to participation
in and/or presentation at certain investor relations events. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's current
and future filings with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 10-K filed on
February 20, 2024.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-participation-in-jefferies-london-healthcare-conference-and-plans-for-investor-rd-day-302302062.html
SOURCE IDEAYA Biosciences, Inc.